Abstract
Polymyxins were discovered in the 1940s and were used to treat infections caused by gram-negative bacteria. These molecules act by destroying the cell membrane through the destabilization of phospholipids and lipopolysaccharides (LPS). Due to adverse effects, such as nephrotoxicity and neurotoxicity, this class had seen limited use. However, with the evolution of antimicrobial resistance to commercial drugs, the use of polymyxins has resumed, and over time, strains resistant to this drug have been observed. Currently, resistant bacteria this antimicrobial are found in hospital environments, and non-anthropized environments. This occurrence constitutes a global human and environmental health problem that is of concern to the population, health professionals, and researchers. Thus, this review was conducted with the objective of describing the mechanisms and the occurrence of bacterial resistance to polymyxins, and to demonstrate the relationship between multi-resistant strains of clinical and environmental origins.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.